HomeComparePERT vs JNJ

PERT vs JNJ: Dividend Comparison 2026

PERT yields 500000.00% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PERT wins by $4.663521010693878e+33M in total portfolio value
10 years
PERT
PERT
● Live price
500000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.663521010693878e+33M
Annual income
$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00
Full PERT calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — PERT vs JNJ

📍 PERT pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPERTJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PERT + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
PERT pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PERT
Annual income on $10K today (after 15% tax)
$42,500,000.00/yr
After 10yr DRIP, annual income (after tax)
$3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, PERT beats the other by $3,962,433,917,637,946,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PERT + JNJ for your $10,000?

PERT: 50%JNJ: 50%
100% JNJ50/50100% PERT
Portfolio after 10yr
$2.331760505346939e+33M
Annual income
$2,330,843,480,963,498,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.96%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

PERT
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PERT buys
0
JNJ buys
0
No recent congressional trades found for PERT or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPERTJNJ
Forward yield500000.00%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$4.663521010693878e+33M$30.5K
Annual income after 10y$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$4,749.88
Total dividends collected$4.6634009849658873e+33M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: PERT vs JNJ ($10,000, DRIP)

YearPERT PortfolioPERT Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$50,010,700$50,000,000.00$10,594$274.49+$50.00MPERT
2$233,748,371,262$233,694,859,813.08$11,294$360.69+$233748.36MPERT
3$1,021,074,511,412,696$1,020,824,400,655,446.10$12,133$476.91+$1021074511.40MPERT
4$4,168,597,328,794,951,700$4,167,504,779,067,739,000.00$13,156$635.42+$4168597328794.94MPERT
5$15,905,475,114,600,665,000,000$15,901,014,715,458,854,000,000.00$14,432$854.61+$15905475114600664.00MPERT
6$56,718,938,532,531,060,000,000,000$56,701,919,674,158,435,000,000,000.00$16,056$1,162.76+$56718938532531060736.00MPERT
7$189,031,807,435,623,860,000,000,000,000$188,971,118,171,394,040,000,000,000,000.00$18,175$1,604.53+$1.8903180743562385e+23MPERT
8$588,799,810,476,518,260,000,000,000,000,000$588,597,546,442,562,100,000,000,000,000,000.00$21,009$2,252.68+$5.8879981047651824e+26MPERT
9$1,714,064,268,114,722,600,000,000,000,000,000,000$1,713,434,252,317,512,700,000,000,000,000,000,000.00$24,911$3,229.73+$1.7140642681147225e+30MPERT
10$4,663,521,010,693,878,300,000,000,000,000,000,000,000$4,661,686,961,926,996,000,000,000,000,000,000,000,000.00$30,458$4,749.88+$4.663521010693878e+33MPERT

PERT vs JNJ: Complete Analysis 2026

PERTStock

Permanent Technologies, Inc. manufactures, designs, and engineers vibration proof fastening systems in the United States and internationally. It primarily offers the TineLok product, a patented, one-way nut and bolt combination, which locks the nut and bolt at predefined positions, eliminating the possibility that vibration may loosen the nut or bolt. The company's fastener assemblies include hex, socket, square, metric hex, metric socket, and metric square head bolts and nuts. Its products are used in various applications, such as automotive, plumbing/valve assemblies, aerospace, marine/military, research and private, defense, agriculture, structural, railways, electronic and medical, as well as highway, bridge, and tunnel applications. Permanent Technologies, Inc. was incorporated in 1994 and is headquartered in Quincy, Massachusetts.

Full PERT Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this PERT vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PERT vs SCHDPERT vs JEPIPERT vs OPERT vs KOPERT vs MAINPERT vs ABBVPERT vs MRKPERT vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.